Hemiasterlin
| Code | Size | Price |
|---|
| TAR-T32055-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32055-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Hemiasterlin is a cytotoxic peptide that acts by inducing mitotic arrest and abnormal spindle formation.
CAS:
157207-90-4
Molecular Weight:
526.71
Purity:
0.98
SMILES:
C([C@@H](C(N[C@H](C(N([C@H](/C=C(/C(O)=O)\C)C(C)C)C)=O)[C@@](C)(C)C)=O)NC)(C)(C)C=1C=2C(N(C)C1)=CC=CC2
References
Marchetti P, Pavan B, Simoni D, Baruchello R, Rondanin R, Mischiati C, Feriotto G, Ferraro L, Hsu LC, Lee RM, Dalpiaz A. A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach. Eur J Pharm Sci. 2016 Aug 25;91:50-63. doi: 10.1016/j.ejps.2016.05.032. Epub 2016 Jun 1. PubMed PMID: 27262542.
Lang JH, Jones PG, Lindel T. Total Synthesis of the Marine Natural Product Hemiasterlin by Organocatalyzed ?-Hydrazination. Chemistry. 2017 Sep 18;23(52):12714-12717. doi: 10.1002/chem.201702812. Epub 2017 Aug 16. PubMed PMID: 28727177.
Lai WT, Cheng KL, Baruchello R, Rondanin R, Marchetti P, Simoni D, Lee RM, Guh JH, Hsu LC. Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth. Biochem Pharmacol. 2016 Aug 1;113:12-23. doi: 10.1016/j.bcp.2016.06.010. Epub 2016 Jun 17. PubMed PMID: 27328368.
Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, ?rum-Madsen MS, Agerb?k M?, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenh?fer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10. PubMed PMID: 28408175.